The stock of TC BioPharm (Holdings) plc ADR (TCBP) has gone down by -54.96% for the week, with a -63.33% drop in the past month and a -71.63% drop in the past quarter. The volatility ratio for the week is 37.18%, and the volatility levels for the past 30 days are 19.97% for TCBP. The simple moving average for the last 20 days is -58.01% for TCBP stock, with a simple moving average of -78.89% for the last 200 days.
Is It Worth Investing in TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP) Right Now?
The 36-month beta value for TCBP is also noteworthy at 0.12. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The average trading volume of TCBP on October 22, 2024 was 242.90K shares.
TCBP) stock’s latest price update
TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s stock price has decreased by -55.14 compared to its previous closing price of 5.06. However, the company has seen a -54.96% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2024-10-03 that TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching process The software could have additional applications across cell therapy for donor/patient matching EDINBURGH, Scotland, Oct. 3, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a sponsored research agreement with Carnegie Mellon University to explore the potential use of artificial intelligence to optimize the patient screening process. The Company will partner with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the School of Computer Science at the renowned university, and her lab to leverage AI to build a solution that enhances the donor selection process and matching process.
TCBP Trading at -57.86% from the 50-Day Moving Average
After a stumble in the market that brought TCBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.36% of loss for the given period.
Volatility was left at 19.97%, however, over the last 30 days, the volatility rate increased by 37.18%, as shares sank -63.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.46% lower at present.
During the last 5 trading sessions, TCBP fell by -54.96%, which changed the moving average for the period of 200-days by -89.82% in comparison to the 20-day moving average, which settled at $5.41. In addition, TC BioPharm (Holdings) plc ADR saw -92.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TCBP
The total capital return value is set at -5.95.
Based on TC BioPharm (Holdings) plc ADR (TCBP), the company’s capital structure generated 0.62 points at debt to capital in total, while cash flow to debt ratio is standing at -6.11.
Currently, EBITDA for the company is -13.61 million with net debt to EBITDA at -0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.64.
Conclusion
In summary, TC BioPharm (Holdings) plc ADR (TCBP) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
